NSA Digital Archive/iStock via Getty Images Shares of Xeris Biopharma ( NASDAQ: XERS ) jumped 14% Thursday morning after the company reported positive topline data from a Phase 2 study of its drug XP-8121, a once-weekly, subcutaneous formulation of the drug levothyroxine for the treatment of hypothyroidism. The product is formulated using Xeris’s XeriSol technology. Xeris said patients in the study showed normalized TSH/T4 levels using 45% less medication than would have been needed had they taken an oral formulation of the drug.
Xeris said it expects to meet with the FDA to discuss the Phase 2 results and facilitate a Phase 3 program for the product by the end of the year. More on Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Pharmaceuticals Q1 2024 Earnings Preview Xeris gains as Oppenheimer highlights drug technology.
